Strong demand in the private phase validates the company’s business model and accelerates its international expansion
Madrid, Spain – 2EyesVision, a European healthtech company focused on patient-centered innovation in ophthalmology, has opened the public phase of its ongoing investment round on Capital Cell, following a highly successful [CD1] [CV2] private phase. At the time of opening to the public, the round is already 70–75% covered, reflecting strong demand from existing shareholders, strategic partners and early supporters. This level of commitment provides solid validation of the company’s business model, market positioning and growth plan.
The round is being conducted entirely on Capital Cell, Europe’s leading investment platform specialized in life sciences and healthcare. Moving from private to public phase allows a wider group of investors to access an opportunity that has already demonstrated traction and investor confidence.
The funds raised will be used to accelerate international expansion, reinforce commercial execution in key markets and support the continued scaling of SimVis Gekko, 2EyesVision’s visual simulation technology for cataract and refractive surgery. The company is focused on consolidating SimVis Gekko as a pre-surgical standard in clinics adopting premium and personalized ophthalmic solutions.
“Reaching the public phase with most of the round already secured confirms the strength of our momentum,” said Carlos Dorronsoro, CEO and co-founder of 2EyesVision. “This round is about scaling a proven solution, expanding internationally and building long-term value in a growing global market.”
Founded as a spin-off from the Spanish National Research Council (CSIC), 2EyesVision has transitioned from research-driven innovation to commercial execution, with its technology already adopted by clinics in multiple international markets. The company operates at the intersection of healthcare, deep tech and patient experience, addressing a clear unmet need in pre-surgical decision-making.
